$ALT
Altimmune, Inc. Stock $alt

$alt Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000156459020052524 Filed on November 09, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q4
Revenue	$2.310M	$2.938M	$580.0K
YoY Change	298.28%	356.23%	-77.61%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.110M	$4.220M	$2.010M
YoY Change	104.48%	92.69%	-16.94%
% of Gross Profit
Research & Development	$8.950M	$17.04M	$2.870M
YoY Change	211.85%	95.22%	-6.21%
% of Gross Profit
Depreciation & Amortization	$120.0K	$100.0K	$70.00K
YoY Change	71.43%	11.11%	-30.0%
% of Gross Profit
Operating Expenses	$13.06M	$21.26M	$4.890M
YoY Change	167.08%	78.41%	-10.77%
Operating Profit		-$18.32M
YoY Change		62.54%
Interest Expense	$40.00K	$2.275K	$190.0K
YoY Change	-78.95%	200.93%	850.0%
% of Operating Profit
Other Income/Expense, Net	-$20.00K	$72.07K	$20.00K
YoY Change	-200.0%	-73.85%	-300.0%
Pretax Income	-$10.73M	-$18.25M	-$4.100M
YoY Change	161.71%	65.96%	-85.0%
Income Tax	-$110.0K	-$482.0K	$0.00
% Of Pretax Income
Net Earnings	-$10.62M	-$17.77M	-$4.100M
YoY Change	159.02%	62.44%	-83.27%
Net Earnings / Revenue	-459.74%	-604.84%	-706.9%
Basic Earnings Per Share		-$0.54
Diluted Earnings Per Share	-$292.0K	-$0.54	-$272.2K
COMMON SHARES
Basic Shares Outstanding	33.07M		15.34M
Diluted Shares Outstanding

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$215.9M	$206.8M	$37.20M
YoY Change	480.38%	427.55%	10.39%
Cash & Equivalents	$115.9M	$143.5M	$8.963M
Short-Term Investments	$100.0M	$63.30M	$28.30M
Other Short-Term Assets	$1.900M	$1.300M	$500.0K
YoY Change	280.0%	225.0%	-54.55%
Inventory
Prepaid Expenses
Receivables	$4.600M	$3.800M	$1.000M
Other Receivables	$7.800M	$6.200M	$700.0K
Total Short-Term Assets	$230.3M	$218.1M	$39.39M
YoY Change	484.49%	424.05%	0.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.057M	$1.042M	$1.104M
YoY Change	-4.28%	-10.39%	-17.77%
Goodwill			$0.00
YoY Change
Intangibles	$12.82M	$12.79M	$12.73M
YoY Change	0.72%	0.42%	-8.08%
Long-Term Investments
YoY Change
Other Assets	$977.2K	$87.20K	$128.5K
YoY Change	660.22%	-38.74%	-30.02%
Total Long-Term Assets	$14.86M	$14.86M	$14.66M
YoY Change	1.33%	0.68%	-4.65%
TOTAL ASSETS
Total Short-Term Assets	$230.3M	$218.1M	$39.39M
Total Long-Term Assets	$14.86M	$14.86M	$14.66M
Total Assets	$245.1M	$233.0M	$54.06M
YoY Change	353.43%	313.2%	-1.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$612.3K	$874.9K	$18.23K
YoY Change	3258.34%	1653.84%	-95.11%
Accrued Expenses	$11.41M	$5.419M	$3.905M
YoY Change	192.16%	134.4%	-4.36%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due			$0.00
YoY Change			-100.0%
Total Short-Term Liabilities	$12.02M	$6.294M	$3.923M
YoY Change	206.41%	155.14%	-13.35%
LONG-TERM LIABILITIES
Long-Term Debt	$1.828M	$1.926M	$1.865M
YoY Change	-1.95%	7.75%	0.69%
Other Long-Term Liabilities	$110.3K	$115.3K	$130.2K
YoY Change	-15.27%	-48.81%	-7.06%
Total Long-Term Liabilities	$1.939M	$2.041M	$1.995M
YoY Change	-2.82%	1.42%	0.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$12.02M	$6.294M	$3.923M
Total Long-Term Liabilities	$1.939M	$2.041M	$1.995M
Total Liabilities	$19.24M	$33.29M	$8.538M
YoY Change	125.34%	375.29%	32.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$186.4M	-$175.8M	-$137.4M
YoY Change	35.7%	31.9%	17.56%
Common Stock	$3.697K	$3.289K	$1.508K
YoY Change	145.16%	118.97%	72.15%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$225.9M	$199.7M	$45.52M
YoY Change
Total Liabilities & Shareholders Equity	$245.1M	$233.0M	$54.06M
YoY Change	353.43%	313.2%	-1.26%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q4
OPERATING ACTIVITIES
Net Income	-$10.62M	-$17.77M	-$4.100M
YoY Change	159.02%	62.44%	-83.27%
Depreciation, Depletion And Amortization	$120.0K	$100.0K	$70.00K
YoY Change	71.43%	11.11%	-30.0%
Cash From Operating Activities	-$13.42M	-$9.500M	-$2.000M
YoY Change	571.0%	290.95%	-61.24%
INVESTING ACTIVITIES
Capital Expenditures	-$140.0K	-$80.00K	$0.00
YoY Change		700.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$36.72M	-$47.81M	-$50.00K
YoY Change	73340.0%	69.48%
Cash From Investing Activities	-$36.86M	-$47.89M	-$60.00K
YoY Change	61333.33%	69.76%	500.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	22.71M	136.1M	40.00K
YoY Change	56675.0%	-272380.0%	-99.87%
NET CHANGE
Cash From Operating Activities	-13.42M	-9.500M	-2.000M
Cash From Investing Activities	-36.86M	-47.89M	-60.00K
Cash From Financing Activities	22.71M	136.1M	40.00K
Net Change In Cash	-27.57M	78.75M	-2.020M
YoY Change	1264.85%	-356.6%	-107.67%
FREE CASH FLOW
Cash From Operating Activities	-$13.42M	-$9.500M	-$2.000M
Capital Expenditures	-$140.0K	-$80.00K	$0.00
Free Cash Flow	-$13.28M	-$9.420M	-$2.000M
YoY Change	564.0%	289.26%	-61.17%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Amendment Flag AmendmentFlag	false
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	143495266
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	45520146
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	33073035
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-2726770
	dei	Entity Address Address Line1 EntityAddressAddressLine1	910 Clopper Road
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 201S
	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20878
	dei	City Area Code CityAreaCode	(240)
	dei	Local Phone Number LocalPhoneNumber	654-1450
	dei	Document Type DocumentType	10-Q
	dei	Security12b Title Security12bTitle	Common stock, par value $0.0001 per share
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	33071020
	dei	Entity File Number EntityFileNumber	001-32587
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54058020
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15312381
	dei	Trading Symbol TradingSymbol	ALT
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001326190
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2019Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	2750000
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	28277386
CY2019Q4	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	1864875
CY2019Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1021179
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8996860
CY2020Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	3816489
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q3	us-gaap	Short Term Investments ShortTermInvestments	63282716
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	25070000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3922999
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8962686
CY2019Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	470228
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-175798822
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5042272
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5020156
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1104208
CY2019Q4	us-gaap	Assets Current AssetsCurrent	39394749
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	199705835
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12794806
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	87195
CY2020Q3	us-gaap	Assets Assets	232995320
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18232
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	874885
CY2020Q3	alt	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	5418831
CY2019Q4	alt	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	3904767
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6293716
CY2020Q3	us-gaap	Other Long Term Debt Noncurrent OtherLongTermDebtNoncurrent	1925769
CY2020Q3	us-gaap	Restricted Cash Current RestrictedCashCurrent	34174
CY2019Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	34174
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	3289
CY2020Q3	us-gaap	Liabilities Liabilities	33289485
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-137376122
CY2020Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	143529440
CY2019Q4	us-gaap	Liabilities Liabilities	8537874
CY2020Q3	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	6193855
CY2019Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	629096
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	1508
CY2020Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1309044
CY2020Q3	us-gaap	Assets Current AssetsCurrent	218131544
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1041920
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	939855
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	12732195
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	698321
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	128547
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	380543640
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	187914916
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2937991
	dei	Entity Registrant Name EntityRegistrantName	ALTIMMUNE, INC.
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5872321
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17041975
CY2019Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1000000
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1000000
	us-gaap	Operating Expenses OperatingExpenses	22378424
	us-gaap	Operating Income Loss OperatingIncomeLoss	-17152824
	alt	Changes In Fair Value Of Warrant Liability ChangesInFairValueOfWarrantLiability	-30000
	us-gaap	Interest Expense InterestExpense	2244
	us-gaap	Investment Income Interest InvestmentIncomeInterest	649268
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-6206
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	670818
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16482006
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-58500
	us-gaap	Net Income Loss NetIncomeLoss	-16423506
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-22116
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	18953
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-17780704
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-10920359
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-38444816
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-16404553
	alt	Deemed Dividends DeemedDividends	452925
CY2020Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	48312566
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	232995320
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2019Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15312167
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	643978
CY2020Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	33073035
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	5225600
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40823756
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8729697
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4220238
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	14892464
CY2019Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2187661
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9097511
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6485960
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	21262213
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	11917358
	us-gaap	Operating Expenses OperatingExpenses	49921267
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-18324222
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-11273380
	us-gaap	Operating Income Loss OperatingIncomeLoss	-44048946
CY2019Q3	alt	Changes In Fair Value Of Warrant Liability ChangesInFairValueOfWarrantLiability	-76000
CY2019Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.74
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.74
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.35
CY2020Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33056971
CY2019Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14768931
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22058424
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12481494
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	214921
CY2020Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-17079
CY2020Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	56739
CY2020Q1	alt	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	39974
CY2020Q1	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-32435
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-3885649
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	41896617
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	330510
CY2020Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36175
CY2020Q2	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-46389
CY2020Q2	alt	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	31270163
CY2020Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	20888
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-16766916
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1320089
CY2020Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	90270
CY2020Q3	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	-114572
CY2020Q3	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	78732
CY2020Q3	alt	Stock Issued During Period Value Common Stock And Pre Funded Warrants In Public Offering Net StockIssuedDuringPeriodValueCommonStockAndPreFundedWarrantsInPublicOfferingNet	124027815
CY2020Q3	alt	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	9728321
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	407714
CY2019Q1	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	28
CY2019Q1	alt	Stock Issued During Period Value Exercise Of Warrants StockIssuedDuringPeriodValueExerciseOfWarrants	30324
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-2097306
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	59322110
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	289772
CY2019Q2	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	28
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-3386888
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	56225022
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	287774
CY2019Q3	us-gaap	Restricted Stock Value Shares Issued Net Of Tax Withholdings RestrictedStockValueSharesIssuedNetOfTaxWithholdings	28
CY2019Q3	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	3791485
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	22320000
	us-gaap	Share Based Compensation ShareBasedCompensation	985260
	us-gaap	Depreciation Depreciation	181314
	us-gaap	Adjustment For Amortization AdjustmentForAmortization	135664
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	3310
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-30000
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2815343
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-179298
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2449447
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	636943
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	856653
	alt	Payments Of Deferred Offering Costs PaymentsOfDeferredOfferingCosts	160522
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	41038458
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	30324
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	25614836
	alt	Proceeds From Issuance Of Common Stock And Pre Funded Warrants In Public Offering Net ProceedsFromIssuanceOfCommonStockAndPreFundedWarrantsInPublicOfferingNet	124027815
	alt	Proceeds From Issuance Of Common Stock In Registered Direct Offering Net ProceedsFromIssuanceOfCommonStockInRegisteredDirectOfferingNet	12668784
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	632000
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	632000
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	186940
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	135471
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	126445
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-322976
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1199708
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2274497
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	5564759
	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-40376
	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	58500
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-21023255
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7599945
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	39385689
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	74413135
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	28207073
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	100329
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1227
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	98893
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	25396
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-35226668
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28233696
	us-gaap	Payments For Repurchase Of Warrants PaymentsForRepurchaseOfWarrants	25000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	190782503
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	12487168
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	134532580
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-23346473
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34353129
CY2019Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11006656
	us-gaap	Interest Paid Net InterestPaidNet	1791
	alt	Common Stock Issued For Acquired In Process Research And Development CommonStockIssuedForAcquiredInProcessResearchAndDevelopment	3791485
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:6.25%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. The extent to which the COVID-19 pandemic may directly or indirectly impact the Company’s business, financial condition, and results of operations is highly uncertain and subject to change. The Company considered the potential impact of the COVID-19 pandemic on the Company’s estimates and assumptions and determined that there was not a material impact to the Company’s consolidated financial statements as of and for the three and nine months ended September 30, 2020. However, actual results could differ from those estimates and there may be changes to the Company’s estimates in future periods.</p>
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	26576
CY2020Q3	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0
CY2020Q3	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Assets Level2 To Level1 Transfers Amount FairValueAssetsLevel2ToLevel1TransfersAmount	0
CY2020Q3	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level1 To Level2 Transfers Amount FairValueLiabilitiesLevel1ToLevel2TransfersAmount	0
CY2020Q3	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2019Q4	us-gaap	Fair Value Liabilities Level2 To Level1 Transfers Amount FairValueLiabilitiesLevel2ToLevel1TransfersAmount	0
CY2020Q3	alt	Assets Or Liabilities Measured At Fair Value On Non Recurring Basis AssetsOrLiabilitiesMeasuredAtFairValueOnNonRecurringBasis	0
CY2020Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1130216
CY2020Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	754377
CY2020Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	375839
CY2020Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	63284825
CY2020Q3	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	-2109
CY2020Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	63282716
CY2020Q3	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	13549183
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	1031323
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	718095
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	313228
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	13450290
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	14539
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	26576
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	26576
CY2020Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	22669
CY2020Q3	alt	Finite Lived Intangible Assets Amortization Expense After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour	258903
	alt	Non Cancellable Lease Maturity Period NonCancellableLeaseMaturityPeriod	2022-12
CY2020Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	107709
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	281603
CY2019Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	84745
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	258824
CY2020Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	64244
	us-gaap	Operating Lease Payments OperatingLeasePayments	190317
CY2020Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	1888604
CY2020Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y6M29D
CY2020Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.074
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	97298
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	475372
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	484484
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	493868
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	503535
CY2020Q3	alt	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	168929
CY2020Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2223486
CY2020Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	334882
CY2020Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	510081
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	429467
CY2020Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1673406
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1183130
CY2020Q3	us-gaap	Interest Payable Current InterestPayableCurrent	10724
CY2019Q4	us-gaap	Interest Payable Current InterestPayableCurrent	5047
CY2020Q3	alt	Accrued Research And Development AccruedResearchAndDevelopment	2876763
CY2019Q4	alt	Accrued Research And Development AccruedResearchAndDevelopment	1966111
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	328104
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	259449
CY2020Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	19753
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	61563
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5418831
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3904767
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1560500
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1484679
CY2020Q3	alt	Economic Conditional Incentive Grants EconomicConditionalIncentiveGrants	250000
CY2019Q4	alt	Economic Conditional Incentive Grants EconomicConditionalIncentiveGrants	250000
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	115269
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	130196
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1925769
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1864875
CY2019Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10384706
	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	1631794
	alt	Number Of Warrants Exercised For Conversion Of Securities NumberOfWarrantsExercisedForConversionOfSecurities	10238889
CY2020Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	1777611
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1622248
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	458609
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	1163639
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.52
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.69
	alt	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageExercisePrice	4.06
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y10M24D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M26D
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	985260
CY2020Q3	us-gaap	Income Tax Examination Liability Refund Adjustment From Settlement With Taxing Authority IncomeTaxExaminationLiabilityRefundAdjustmentFromSettlementWithTaxingAuthority	3900000
CY2020Q3	alt	Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingIntrinsicValue	10698428
	alt	Share Based Compensation Arrangement By Share Based Payment Award Options Unvested Outstanding Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedOutstandingWeightedAverageRemainingContractualTerm	P5Y11M15D
CY2020Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15235853
CY2020Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	4537424
CY2020Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1320089
CY2019Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	287775
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1865520
	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-1400000
CY2020Q3	us-gaap	Tax Adjustments Settlements And Unusual Provisions TaxAdjustmentsSettlementsAndUnusualProvisions	-500000

Files In Submission

Name	View Source	Status
0001564590-20-052524-index-headers.html	Edgar Link	pending
0001564590-20-052524-index.html	Edgar Link	pending
0001564590-20-052524.txt	Edgar Link	pending
0001564590-20-052524-xbrl.zip	Edgar Link	pending
alt-10q_20200930.htm	Edgar Link	pending
alt-20200930.xml	Edgar Link	completed
alt-20200930.xsd	Edgar Link	pending
alt-20200930_cal.xml	Edgar Link	unprocessable
alt-20200930_def.xml	Edgar Link	unprocessable
alt-20200930_lab.xml	Edgar Link	unprocessable
alt-20200930_pre.xml	Edgar Link	unprocessable
alt-ex101_236.htm	Edgar Link	pending
alt-ex102_237.htm	Edgar Link	pending
alt-ex311_8.htm	Edgar Link	pending
alt-ex312_6.htm	Edgar Link	pending
alt-ex321_10.htm	Edgar Link	pending
alt-ex322_11.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gqh5kkem4z5h000001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALT
Altimmune, Inc. Stock $alt

2020 Q4 Form 10-Q Financial Statement

#000156459020052524 Filed on November 09, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT Altimmune, Inc. Stock $alt

2020 Q4 Form 10-Q Financial Statement

#000156459020052524 Filed on November 09, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALT
Altimmune, Inc. Stock $alt